Stockscreener 앱 받기
3.06
2.34%
0.07
시간 외 거래:
3.06
Atea Pharmaceuticals Inc 주식(AVIR)의 최신 뉴스
Short Interest in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Decreases By 12.9% - MarketBeat
JPMorgan Chase & Co. Grows Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals director Franklin Berger acquires $81,498 in stock - MSN
Franklin Berger Increases Stake in Atea Pharmaceuticals Inc (AVI - GuruFocus.com
Barclays PLC Buys 75,624 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - MarketBeat
Barclays PLC Has $593,000 Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Atea Pharmaceuticals Targets $3B HCV Market with Phase 3 Trial Launch, Backed by $454M Cash - StockTitan
Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Atea Pharmaceuticals CEO to Present Business Update at J.P. Morgan Healthcare Conference - StockTitan
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Stock Position Decreased by Geode Capital Management LLC - Defense World
Barclays PLC Increases Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Short Interest Update - MarketBeat
State Street Corp Purchases 11,566 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
US Penny Stocks To Watch In December 2024 - Simply Wall St
Atea Pharmaceuticals Faces Shareholder Revolt Over Director's Stock Sale, Strategic Decisions - StockTitan
Atea Pharmaceuticals engages Evercore to explore partnerships - MSN
Analyzing Atea Pharmaceuticals (NASDAQ:AVIR) & Alnylam Pharmaceuticals (NASDAQ:ALNY) - Defense World
Atea Pharmaceuticals, Inc. Engages Evercore to Identify Potential Opportunities to Enhance Shareholder Value, Including the Exploration of Strategic Partnerships Related to Its Phase 3-Ready Program for the Treatment of Hepatitis C Virus - Marketscreener.com
Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships - GlobeNewswire
Atea Pharmaceuticals Taps Evercore to Explore Strategic Options for Phase 3 HCV Program - StockTitan
Charles Schwab Investment Management Inc. Acquires 50,794 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals director Franklin Berger sells $1.02 million in stock By Investing.com - Investing.com Nigeria
Atea Pharmaceuticals director Franklin Berger sells $1.02 million in stock - Investing.com
Fmr LLC Buys 182,174 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - MarketBeat
Atea Pharmaceuticals stock hits 52-week low at $2.88 By Investing.com - Investing.com Australia
Atea Pharmaceuticals stock hits 52-week low at $2.88 - Investing.com
Atea Pharmaceuticals announces results from Phase 2 regimen of bemnifosbuvir - Yahoo Finance
Atea Aims For Underserved HCV Niche With Combo Regimen - News & Insights
After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study - Yahoo Finance
Atea reports high efficacy in Phase 2 HCV treatment study - Investing.com
Atea Pharmaceuticals Announces Positive Results from Phase - GlobeNewswire
Atea's HCV Drug Achieves 98% Cure Rate in Phase 2 Trial, Shows Breakthrough Promise - StockTitan
Atea plans Phase 3 study for hepatitis C drug after mid-stage results - Yahoo Finance
Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference - GlobeNewswire
Atea Pharmaceuticals CEO to Present at Evercore HealthCONx Conference | AVIR Stock News - StockTitan
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year? - MSN
Island Pharmaceuticals Advances Dengue Clinical Trial - MSN
Atomo Diagnostics Plans Share Issuance to Boost Capital - MSN
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024 - GlobeNewswire
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024 - GlobeNewswire Inc.
FMR LLC Increases Stake in Atea Pharmaceuticals Inc - GuruFocus.com
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) is BML Capital Management LLC's 3rd Largest Position - MarketBeat
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2024 Earnings Call Transcript - Insider Monkey
Atea Pharmaceuticals Advances in HCV Treatment Development - TipRanks
Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Atea Reports $31.2M Loss, Exits COVID Program Despite Strong HCV Pipeline Results | AVIR Stock News - StockTitan
3.95%
2.39%
자본화:
|
볼륨(24시간):